Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

About this update from Sonoma Pharmaceuticals, Inc.

[{"type":"text","content":"BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) to be sold through a prominent U.K. health and beauty retailer and pharmacy chain across more than 1,200 stores throughout the United Kingdom.","length":659,"tagName":"p"},{"type":"text","content":"The innovative product line includes an acne toner and a balancing serum, both of which are available under the retailer's own brand name.","length":142,"tagName":"p"},{"type":"text","content":""We are excited to bring our safe and effective acne line to consumers in the United Kingdom and to expand our range of distribution in Europe," said Amy Trombly, CEO of Sonoma. "These products utilize all-natural hypochlorous acid and our patented Microcyn technology formulation, providing a safe and gentle alternative to products containing harsh ingredients such as alcohol and benzoyl peroxide."","length":421,"tagName":"p"},{"type":"text","content":"About Sonoma Pharmaceuticals, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands....

More updates from Sonoma Pharmaceuticals, Inc.